drugset
drugset / Trial / NCT02953782

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

NCT02953782 ↗

Phase 1/2 Completed 78 enrolled Gilead Sciences California Institute for Regenerative Medicine (CIRM) · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

Timeline

Start
2016-11-02
Primary completion
2020-02-10
Completion
2020-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 200 mg/m2 Intravenous
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Subject Magrolimab Monoclonal antibody 10 mg/kg Intravenous
Subject Magrolimab Monoclonal antibody 20 mg/kg Intravenous
Subject Magrolimab Monoclonal antibody 30 mg/kg Intravenous
Subject Magrolimab Monoclonal antibody 45 mg/kg Intravenous

Indications

colorectal cancer